Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P49753
UPID:
ACOT2_HUMAN
Alternative names:
Acyl-coenzyme A thioester hydrolase 2a; CTE-Ia; Long-chain acyl-CoA thioesterase 2; ZAP128
Alternative UPACC:
P49753; Q3I5F8; Q53EK4; Q9NUX4
Background:
Acyl-coenzyme A thioesterase 2, mitochondrial, also known as Acyl-coenzyme A thioester hydrolase 2a, CTE-Ia, Long-chain acyl-CoA thioesterase 2, and ZAP128, plays a crucial role in fatty acid metabolism. It catalyzes the hydrolysis of acyl-CoAs into free fatty acids and coenzyme A, particularly effective with long chain acyl CoAs (C14-C20), thereby regulating their intracellular levels and supporting hepatic fatty acid oxidation in mitochondria.
Therapeutic significance:
Understanding the role of Acyl-coenzyme A thioesterase 2 could open doors to potential therapeutic strategies.